Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $18.04, for a total transaction of $120,272.68. Following the transaction, the chief operating officer now owns 316,643 shares in the company, valued at approximately $5,712,239.72. The trade was a 2.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Anish Patel also recently made the following trade(s):
- On Friday, March 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48.
- On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31.
Enliven Therapeutics Price Performance
Enliven Therapeutics stock opened at $16.52 on Thursday. Enliven Therapeutics, Inc. has a 12 month low of $14.47 and a 12 month high of $30.03. The company has a market cap of $809.55 million, a PE ratio of -8.69 and a beta of 1.03. The company has a fifty day moving average price of $20.56 and a two-hundred day moving average price of $23.41.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have recently issued reports on ELVN. HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a "buy" rating and a $42.00 price target for the company.
Check Out Our Latest Stock Analysis on Enliven Therapeutics
Institutional Investors Weigh In On Enliven Therapeutics
Several institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its position in Enliven Therapeutics by 10.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company's stock worth $6,520,000 after acquiring an additional 24,043 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock valued at $441,000 after buying an additional 3,518 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Enliven Therapeutics by 12.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock valued at $668,000 after buying an additional 2,944 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $271,000. Finally, State Street Corp grew its stake in shares of Enliven Therapeutics by 2.9% in the 3rd quarter. State Street Corp now owns 745,944 shares of the company's stock valued at $19,051,000 after buying an additional 21,018 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
